Founded in Jupiter, United States, Cytonics is a biotechnology company dedicated to the research and development of diagnostics and therapeutics for osteoarthritis. Their core mission is to improve the diagnosis and treatment of musculoskeletal-related pain. The company's flagship product, the Fibronectin-Aggrecan Complex Test (FACT™), detects cartilage damage from osteoarthritis using joint fluid samples. This innovative diagnostic tool has been licensed to Synthes, which was later acquired by Johnson & Johnson, and has been utilized by numerous physicians.

Cytonics has garnered attention for its impactful contributions to the field of osteoarthritis diagnostics. The licensing of FACT™ to Synthes represents a significant milestone, demonstrating the product's clinical utility and commercial viability. The company's work has improved the ability of healthcare providers to diagnose and treat osteoarthritis, thereby enhancing patient outcomes. Through ongoing innovation and strategic partnerships, Cytonics continues to influence the biotechnology landscape positively.